281 related articles for article (PubMed ID: 28343201)
1. [Ibrutinib - new tool in hematologist hand, new challenges for internist].
Majcherek M; Dworacka M; Dworacki G
Wiad Lek; 2017; 70(1):92-95. PubMed ID: 28343201
[TBL] [Abstract][Full Text] [Related]
2. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.
Byrd JC; Furman RR; Coutre SE; Flinn IW; Burger JA; Blum KA; Grant B; Sharman JP; Coleman M; Wierda WG; Jones JA; Zhao W; Heerema NA; Johnson AJ; Sukbuntherng J; Chang BY; Clow F; Hedrick E; Buggy JJ; James DF; O'Brien S
N Engl J Med; 2013 Jul; 369(1):32-42. PubMed ID: 23782158
[TBL] [Abstract][Full Text] [Related]
3. The safety of Bruton's tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia.
Tran PN; O'Brien S
Expert Opin Drug Saf; 2017 Sep; 16(9):1079-1088. PubMed ID: 28627951
[TBL] [Abstract][Full Text] [Related]
4. Ibrutinib: first global approval.
Cameron F; Sanford M
Drugs; 2014 Feb; 74(2):263-71. PubMed ID: 24464309
[TBL] [Abstract][Full Text] [Related]
5. Development of the Bruton's tyrosine kinase inhibitor ibrutinib for B cell malignancies.
Gayko U; Fung M; Clow F; Sun S; Faust E; Price S; James D; Doyle M; Bari S; Zhuang SH
Ann N Y Acad Sci; 2015 Nov; 1358():82-94. PubMed ID: 26348626
[TBL] [Abstract][Full Text] [Related]
6. Ibrutinib: a new frontier in the treatment of chronic lymphocytic leukemia by Bruton's tyrosine kinase inhibition.
Dias AL; Jain D
Cardiovasc Hematol Agents Med Chem; 2013 Dec; 11(4):265-71. PubMed ID: 24433470
[TBL] [Abstract][Full Text] [Related]
7. Successful use of Bruton's kinase inhibitor, ibrutinib, to control paraneoplastic pemphigus in a patient with paraneoplastic autoimmune multiorgan syndrome and chronic lymphocytic leukaemia.
Lee A; Sandhu S; Imlay-Gillespie L; Mulligan S; Shumack S
Australas J Dermatol; 2017 Nov; 58(4):e240-e242. PubMed ID: 28295171
[TBL] [Abstract][Full Text] [Related]
8. [Ibrutinib: A new drug of B-cell malignancies].
Thieblemont C
Bull Cancer; 2015 Jun; 102(6 Suppl 1):S85-90. PubMed ID: 26118882
[TBL] [Abstract][Full Text] [Related]
9. Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT.
Ryan CE; Sahaf B; Logan AC; O'Brien S; Byrd JC; Hillmen P; Brown JR; Dyer MJ; Mato AR; Keating MJ; Jaglowski S; Clow F; Rezvani AR; Styles L; Coutre SE; Miklos DB
Blood; 2016 Dec; 128(25):2899-2908. PubMed ID: 27802969
[TBL] [Abstract][Full Text] [Related]
10. Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
Burger JA; Tedeschi A; Barr PM; Robak T; Owen C; Ghia P; Bairey O; Hillmen P; Bartlett NL; Li J; Simpson D; Grosicki S; Devereux S; McCarthy H; Coutre S; Quach H; Gaidano G; Maslyak Z; Stevens DA; Janssens A; Offner F; Mayer J; O'Dwyer M; Hellmann A; Schuh A; Siddiqi T; Polliack A; Tam CS; Suri D; Cheng M; Clow F; Styles L; James DF; Kipps TJ;
N Engl J Med; 2015 Dec; 373(25):2425-37. PubMed ID: 26639149
[TBL] [Abstract][Full Text] [Related]
11. The clinical safety of ibrutinib in chronic lymphocytic leukemia.
Molica S
Expert Opin Drug Saf; 2015 Oct; 14(10):1621-9. PubMed ID: 26359217
[TBL] [Abstract][Full Text] [Related]
12. Ibrutinib continues to influence the therapeutic landscape of chronic lymphocytic leukemia: new data presented at ASCO 2017.
Molica S
BMC Med; 2017 Aug; 15(1):156. PubMed ID: 28810856
[TBL] [Abstract][Full Text] [Related]
13. The emerging role of ibrutinib in the treatment of chronic lymphocytic leukemia.
Molica S
Expert Rev Hematol; 2013 Oct; 6(5):543-6. PubMed ID: 24083545
[TBL] [Abstract][Full Text] [Related]
14. FDA grants accelerated approval for ibrutinib for CLL.
Dangi-Garimella S
Am J Manag Care; 2014 Mar; 20(5 Spec No.):E10. PubMed ID: 25618623
[No Abstract] [Full Text] [Related]
15. A review of a novel, Bruton's tyrosine kinase inhibitor, ibrutinib.
Lee CS; Rattu MA; Kim SS
J Oncol Pharm Pract; 2016 Feb; 22(1):92-104. PubMed ID: 25425007
[TBL] [Abstract][Full Text] [Related]
16. The impacts of zanubrutinib on immune cells in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
Zou YX; Zhu HY; Li XT; Xia Y; Miao KR; Zhao SS; Wu YJ; Wang L; Xu W; Li JY
Hematol Oncol; 2019 Oct; 37(4):392-400. PubMed ID: 31420873
[TBL] [Abstract][Full Text] [Related]
17. Is HBV prophylaxis required during CLL treatment with ibrutinib?
Tedeschi A; Frustaci AM; Mazzucchelli M; Cairoli R; Montillo M
Leuk Lymphoma; 2017 Dec; 58(12):2966-2968. PubMed ID: 28535112
[No Abstract] [Full Text] [Related]
18. Long-term Efficacy of Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia: Results of the Polish Adult Leukemia Study Group Observational Study.
Pula B; Iskierka-Jazdzewska E; Dlugosz-Danecka M; Szymczyk A; Hus M; Szeremet A; Drozd-Sokolowska J; Waszczuk-Gajda A; Zaucha JM; Holojda J; Piszczek W; Steckiewicz P; Wojciechowska M; Osowiecki M; Knopinska-Posluszny W; Dudzinski M; Zawirska D; Subocz E; Halka J; Pluta A; Wichary R; Kumiega B; Budziszewska BK; Jurczak W; Lech-Maranda E; Giannopoulos K; Robak T; Jamroziak K
Anticancer Res; 2020 Jul; 40(7):4059-4066. PubMed ID: 32620653
[TBL] [Abstract][Full Text] [Related]
19. Progressive Multifocal Leukoencephalopathy after Ibrutinib Therapy for Chronic Lymphocytic Leukemia.
Lutz M; Schulze AB; Rebber E; Wiebe S; Zoubi T; Grauer OM; Keßler T; Kerkhoff A; Lenz G; Berdel WE
Cancer Res Treat; 2017 Apr; 49(2):548-552. PubMed ID: 27456945
[TBL] [Abstract][Full Text] [Related]
20. Ibrutinib in B lymphoid malignancies.
Smith MR
Expert Opin Pharmacother; 2015; 16(12):1879-87. PubMed ID: 26165513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]